Environmental Exposures and the Risk of Hepatocellular Carcinoma

Overview

Journal Hepatol Commun

Date 2025 Jan 15

PMID 39813595

Authors

Divya Rayapati

Katherine A McGlynn

John D Groopman

Amy K Kim

Affiliations

Soon will be listed here.

Abstract

The global epidemiology of HCC is shifting due to changes in both established and emerging risk factors. This transformation is marked by an emerging prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes, alongside traditional risks such as viral hepatitis (HBV and HCV), and exposure to chemical agents like aflatoxin, alcohol, tobacco, and air pollution. This review examines how environmental exposures and evolving liver pathology, exacerbated by lifestyle and metabolic conditions, are contributing to the rising worldwide incidence of HCC. Effective prevention strategies must not only address traditional risk factors through vaccination and therapeutic measures but also confront metabolic and socioeconomic disparities through comprehensive public health efforts. As the burden of liver cancer continues to grow, particularly in resource-limited settings, an expansive and inclusive approach is vital for mitigating its impact across diverse populations.

References

. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022; 7(5):396-415. DOI: 10.1016/S2468-1253(21)00472-6. View

Zamora S, Pinheiro P, Gomez S, Hastings K, Palaniappan L, Hu J . Disaggregating Hispanic American Cancer Mortality Burden by Detailed Ethnicity. Cancer Epidemiol Biomarkers Prev. 2019; 28(8):1353-1363. PMC: 6771432. DOI: 10.1158/1055-9965.EPI-18-0872. View

Lin H, Sung T, Chen C, Guo H . Arsenic levels in drinking water and mortality of liver cancer in Taiwan. J Hazard Mater. 2013; 262:1132-8. DOI: 10.1016/j.jhazmat.2012.12.049. View

Yang X, Yamagiwa S, Ichida T, Matsuda Y, Sugahara S, Watanabe H . Increase of CD4+ CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma. J Hepatol. 2006; 45(2):254-62. DOI: 10.1016/j.jhep.2006.01.036. View

Younossi Z . Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol. 2018; 70(3):531-544. DOI: 10.1016/j.jhep.2018.10.033. View

De Mitri M, Poussin K, Baccarini P, Pontisso P, DErrico A, Simon N . HCV-associated liver cancer without cirrhosis. Lancet. 1995; 345(8947):413-5. DOI: 10.1016/s0140-6736(95)90400-x. View

Younossi Z, Golabi P, Paik J, Henry A, Van Dongen C, Henry L . The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023; 77(4):1335-1347. PMC: 10026948. DOI: 10.1097/HEP.0000000000000004. View

Makarova-Rusher O, Altekruse S, McNeel T, Ulahannan S, Duffy A, Graubard B . Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer. 2016; 122(11):1757-65. PMC: 5548177. DOI: 10.1002/cncr.29971. View

Letouze E, Shinde J, Renault V, Couchy G, Blanc J, Tubacher E . Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis. Nat Commun. 2017; 8(1):1315. PMC: 5670220. DOI: 10.1038/s41467-017-01358-x. View

10.

Jeng W, Lok A . What will it take to cure hepatitis B?. Hepatol Commun. 2023; 7(4). PMC: 10043561. DOI: 10.1097/HC9.0000000000000084. View

11.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

12.

Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M . Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol. 2017; 67(6):1204-1212. DOI: 10.1016/j.jhep.2017.07.025. View

13.

Riazi K, Azhari H, Charette J, Underwood F, King J, Afshar E . The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022; 7(9):851-861. DOI: 10.1016/S2468-1253(22)00165-0. View

14.

Xie X, Zheng M, Guo W, Zhou Y, Xiang Z, Li Y . Correlation analysis of metabolic characteristics and the risk of metabolic-associated fatty liver disease - related hepatocellular carcinoma. Sci Rep. 2022; 12(1):13969. PMC: 9385637. DOI: 10.1038/s41598-022-18197-6. View

15.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

16.

Lai S, Chen P, Liao K, Muo C, Lin C, Sung F . Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol. 2011; 107(1):46-52. DOI: 10.1038/ajg.2011.384. View

17.

Williams P, Zaidi S, Sengupta R . AACR Cancer Disparities Progress Report 2022. Cancer Epidemiol Biomarkers Prev. 2022; 31(7):1249-1250. DOI: 10.1158/1055-9965.EPI-22-0542. View

18.

Gouas D, Shi H, Hainaut P . The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy. Cancer Lett. 2009; 286(1):29-37. DOI: 10.1016/j.canlet.2009.02.057. View

19.

McGlynn K, Petrick J, London W . Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015; 19(2):223-38. PMC: 4712629. DOI: 10.1016/j.cld.2015.01.001. View

20.

Ohkuma T, Peters S, Woodward M . Sex differences in the association between diabetes and cancer: a systematic review and meta-analysis of 121 cohorts including 20 million individuals and one million events. Diabetologia. 2018; 61(10):2140-2154. PMC: 6133170. DOI: 10.1007/s00125-018-4664-5. View